Christine James1, David I Bernstein. 1. Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Allergen immunotherapy is the only modality that can modify the immune response upon exposure to aeroallergens and venom allergens. This review will update the allergist on recent studies evaluating safety of sublingual and subcutaneous allergen immunotherapy. RECENT FINDINGS: Multiple clinical trials and retrospective studies have been published evaluating overall safety of these therapies. The risk of systemic reactions with subcutaneous immunotherapy remains quite low, but near-fatal and fatal anaphylaxis does occur, requiring physicians to be aware of potential risks for such events. Sublingual immunotherapy has a high incidence of local site application reactions, but severe anaphylactic events are very uncommon. SUMMARY: Subcutaneous immunotherapy and sublingual immunotherapy are beneficial in treating allergic rhinitis and venom hypersensitivity but should be administered only by physicians familiar with potential risk factors and able to manage treatment-related local and systemic allergic reactions.
PURPOSE OF REVIEW: Allergen immunotherapy is the only modality that can modify the immune response upon exposure to aeroallergens and venom allergens. This review will update the allergist on recent studies evaluating safety of sublingual and subcutaneous allergen immunotherapy. RECENT FINDINGS: Multiple clinical trials and retrospective studies have been published evaluating overall safety of these therapies. The risk of systemic reactions with subcutaneous immunotherapy remains quite low, but near-fatal and fatal anaphylaxis does occur, requiring physicians to be aware of potential risks for such events. Sublingual immunotherapy has a high incidence of local site application reactions, but severe anaphylactic events are very uncommon. SUMMARY: Subcutaneous immunotherapy and sublingual immunotherapy are beneficial in treating allergic rhinitis and venom hypersensitivity but should be administered only by physicians familiar with potential risk factors and able to manage treatment-related local and systemic allergic reactions.
Authors: Pablo Rodríguez Del Río; Carmen Vidal; Jocelyne Just; Ana I Tabar; Inmaculada Sanchez-Machin; Peter Eberle; Jesus Borja; Petra Bubel; Oliver Pfaar; Pascal Demoly; Moises A Calderón Journal: Pediatr Allergy Immunol Date: 2016-11-03 Impact factor: 6.377
Authors: Linda S Cox; Désirée Larenas Linnemann; Hendrik Nolte; David Weldon; Ira Finegold; Harold S Nelson Journal: J Allergy Clin Immunol Date: 2006-05 Impact factor: 10.793
Authors: Tolly G Epstein; Gary M Liss; Karen Murphy-Berendts; David I Bernstein Journal: Ann Allergy Asthma Immunol Date: 2016-03-03 Impact factor: 6.347
Authors: J Christian Virchow; Vibeke Backer; Piotr Kuna; Luis Prieto; Hendrik Nolte; Hanne Hedegaard Villesen; Christian Ljørring; Bente Riis; Frederic de Blay Journal: JAMA Date: 2016-04-26 Impact factor: 56.272
Authors: Oliver Pfaar; Tobias Ankermann; Matthias Augustin; Petra Bubel; Sebastian Böing; Randolf Brehler; Peter A Eng; Peter J Fischer; Michael Gerstlauer; Eckard Hamelmann; Thilo Jakob; Jörg Kleine-Tebbe; Matthias Volkmar Kopp; Susanne Lau; Norbert Mülleneisen; Christoph Müller; Katja Nemat; Wolfgang Pfützner; Joachim Saloga; Klaus Strömer; Peter Schmid-Grendelmeier; Antje Schuster; Gunter Johannes Sturm; Christian Taube; Zsolt Szépfalusi; Christian Vogelberg; Martin Wagenmann; Wolfgang Wehrmann; Thomas Werfel; Stefan Wöhrl; Margitta Worm; Bettina Wedi; Susanne Kaul; Vera Mahler; Anja Schwalfenberg Journal: Allergol Select Date: 2022-09-06